Biotech Startups Get a Boost: ZAGENO and Hatch.Bio Labs Partner to Streamline Lab Operations
ZAGENO Forms a Strategic Partnership With Hatch.Bio Labs, a Premier Biotech Incubator
BOSTON, MA / ACCESSWIRE / January 8, 2025 / Biotech startups often encounter administrative roadblocks on their path to achieving breakthroughs in life sciences. Today, ZAGENO, the leading AI-powered marketplace for lab supplies, and Hatch.Bio Labs, a premier biotech incubator, join forces to eliminate these challenges.ZAGENO x Hatch.Bio Labs
ZAGENO and Hatch.Bio Labs Partner to Streamline Lab Operations
This strategic partnership empowers Hatch.Bio residents with a streamlined lab supply procurement process, allowing them to prioritize groundbreaking research. ZAGENO's platform offers an Amazon-like shopping experience for lab supplies, featuring:
Effortless Management: Discounted rates, easy price comparison of 5,300+ suppliers, single bill-to options, and automated order tracking.
Dedicated Support: Fast onboarding, procurement best practices, and frequent on-site guidance to maximize platform value.
Reduced Costs: Exclusive discounts for Hatch members, with free access for smaller startups.
"Biotech startups are at the forefront of innovation, but administrative hurdles can delay their progress," says Florian Wegener, CEO and Founder of ZAGENO. "Our partnership with Hatch.Bio simplifies lab supply ordering for their members, saving them valuable time and resources."
James Weis, Hatch.Bio CEO, adds, "This collaboration provides our residents with a critical operational advantage, allowing them to streamline operations and accelerate research."
Through this partnership, Hatch.Bio tenants will gain seamless access to ZAGENO's AI-powered lab supply marketplace. By integrating ZAGENO's platform with Hatch.Bio's facilities and support, this collaboration simplifies procurement, automates tracking, and minimizes administrative tasks, freeing researchers to focus on advancing their research to the clinic.
About ZAGENO
ZAGENO is transforming lab supply procurement with the industry's largest AI-powered marketplace, featuring over 40 million products from 5,300+ global suppliers. Scientists, lab managers, and procurement teams rely on ZAGENO's all-in-one platform for painless lab supply procurement that optimizes budgets and enhances productivity. With automated order and delivery tracking, custom workflows, real-time spend analytics, and offloaded supplier management, ZAGENO empowers labs of all sizes to achieve full lab supply ordering automation. Explore ZAGENO's marketplace and discover how it can streamline your lab supply procurement: www.zageno.com or request access at bit.ly/HatchBio-Labs.
About Hatch.Bio Labs
Hatch.Bio Labs is the premier biotechnology and life sciences incubation platform dedicated to reducing operational barriers for biotechnology and life sciences companies. We provide best-in-class, highly flexible, and cost-effective laboratory and office facilities, natively integrated with comprehensive scientific and operational support and strategic partnerships within a modern technology stack-all to help our resident companies grow more rapidly and efficiently. Our mission is to empower biotech pioneers to develop transformative technologies and advance the pace of biotechnology innovation. For more information and to inquire about becoming a tenant, visit www.hatch.bio.
Contact Information
Stephanie Harold
pr@zageno.com
+1 (857) 477-8479
SOURCE: ZAGENO
View the original press release on accesswire.com
ZAGENO
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom